ImexpharmSTC:IMP -1.38%98 EBITDA Margin % is 23.99% as of Mar. 2026, which is 8% above its 10-year median of 22.29. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Imexpharm ranks better than 77.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Imexpharm's EBITDA for the
three
months ended in Mar. 2026 was ₫131,028 Mil. Imexpharm's Revenue for the
three
months ended in Mar. 2026 was ₫546,206 Mil. Therefore, Imexpharm's EBITDA margin for the quarter that ended in Mar. 2026 was 23.99%.
Imexpharm (STC:IMP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Imexpharm EBITDA Margin % Related Terms
Imexpharm EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Imexpharm's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Imexpharm's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a EBITDA Margin % of 23.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imexpharm and its competitors. This is near median its historical median of 22.29. Over the past decade, Imexpharm's EBITDA Margin % has ranged from 15.32 to 24.23. According to the industry distribution chart, Imexpharm ranks #219 out of 955 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Imexpharm's EBITDA Margin % too high?
Imexpharm's current EBITDA Margin % of 23.99% is near median its 10-year median of 22.29. Over the past 10 years, this metric has ranged from a low of 15.32 to a high of 24.23. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Imexpharm's value of 23.99% is 93.6% above this industry median. Based on the distribution chart, Imexpharm ranks #219 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #219 out of 955 companies for EBITDA Margin %. This places Imexpharm in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Imexpharm's value of 23.99% is 93.6% above this benchmark. Historically, Imexpharm's own EBITDA Margin % has ranged from 15.32 to 24.23 over the past decade. While the company's 10-year median is 22.29 vs. the industry median of 12.39, Imexpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current EBITDA Margin % of 23.99% is 93.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current EBITDA Margin % is 23.99%, which is near median its own 10-year median of 22.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,900.00 — trading 17% below its estimated fair value. The current EBITDA Margin % is 23.99%, which is near median its 10-year median of 22.29 and 93.6% above the Drug Manufacturers industry median of 12.39. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current EBITDA Margin % is 23.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,900.00 is trading 17% below its estimated GF Value™ of ₫51,706.57.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
EBITDA Margin %: 23.99% (near median its 10-year median of 22.29)
GF Value™: ₫51,706.57 vs. price of ₫42,900.00 (17% below fair value)
Industry Position: 93.6% above the Drug Manufacturers median (#219 of 955)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
